Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1997-02-04
1999-06-29
Reeves, Julie
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4351733, 435236, 435237, 435239, 536 231, 536 2372, 530826, A61K 39215, C12N 1515, C12N 704
Patent
active
059165707
ABSTRACT:
New purified and isolated bovine coronavirus (BCV) types (II and III) are described which can be used to create new modified live vaccines for administration to cattle in order to confer immunity against virulent wild-type bovine coronavirus infection. Preferably, a multivalent modified live vaccine is provided for oral-nasal administration which includes the known Type I virus and the new Types II and III virus. Hygromycin B has also demonstrated to be effective for suppressing BCV replication and thus can be administered to cattle as a treatment for the chronic disease and to suppress shedding of BCV in cattle feces.
REFERENCES:
patent: 3838004 (1974-09-01), Mebus et al.
patent: 3839556 (1974-10-01), Mebus et al.
patent: 3869547 (1975-03-01), Mebus et al.
patent: 3914408 (1975-10-01), Mebus
Lai Current Topics in Microbiology and Immunology vol. 176 21-32, 1992.
Kapil et al J Vet Diagn Invest vol 7 538-539, 1995.
Kapil et al J Vet Diagn Invest vol 8 96-99, 1996.
Fields et al Fields Virology Third Edition Lippincott-Raven Publishers Chapter 34, 1996.
Bukh et al Seminars in Liver Disease vol. 15 No 1 41-63, 1995.
Wang et al Virology vol. 192 710-716, 1993.
Keck et al Journalof Virology VOl 62 No 5 1810-1813, May 1988.
Browining et al Cell Vol. 72 847-856, Mar. 1993.
Siddell; the Coronaviridae; Plenum Press, New York, 1995; Chapter I. pp. 1-10.
Benedetto et al 1980 Virology 106: 123-132.
Clark, M.A.; 1993, Bovine coronavirus. Br. Vet. J. 149:51-70.
St. Cyr-Coats, K. et al.; 1988, Bovine coronavirus-induced cytopathic expression and plaque formation: Host cell and virus strain determine trypsin dependence; J. Vet. Sci. B. 35:48-56.
Hirano, N. et al.; 1985. Plaque assay of bovine coronavirus in BEK-1 cells. Jpn. J. Vet Sci. 47: 679-681.
Kapil, S. et al.; 1994. Effect of rolling, spinning and sample preparation on isolation of bovine coronavirus (BDV) in human rectal tumor-18 (HRT-18) cell line. In: Proc. 75.sup.th Conf. Res Workers Anim. Dis., Chicago, IL Nov. 14-15, 1994, 75:P77.
Kapil, S. et al.; 1991. Experimental infection with a virulent pneumoenteric isolate of bovine coronavirus. J. Vet. Diagn. Invest 3:88-89.
Kapil, S. et al.; 1990. Excretion an persistance of the bovine coronavirus in neonatal calves. Arch. Virol. 115:127-132.
Macintyre, G. et al.; 1991a. Hygromycin B therapy of a murine coronaviral hepatitis. Antimicrob. Agents Chemother. 35:2125-2170.
Macintyre G., et al. 1991b. Hygromycine B inhibits synthesis ofmurine coronavirus RNA. Antimicrob. Agents Chemother 35:2630-2633.
Storz, J. et al.; 1981. Enhancement of plaque formation and cell fusion of an enteropathogenic coronavirus by trypsin treatment. Infect. Immun. 31:1214-1222.
Vautherot, J.F. 1981. Plaque assay for titration of bovine enteric coronavirus. J. Gen. Virol. 56:451-455.
Tsunemitsu et al.; 1995. Antigenic and biological comparisons of bovine coronaviruses derived from neonatal alf diarrhea and winter dysentery of adult cattle. Arch. Virol. 140:1303-1311.
Kansas State University Research Foundation
Reeves Julie
LandOfFree
Multivalent bovine coronavirus vaccine and method of treating bo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent bovine coronavirus vaccine and method of treating bo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent bovine coronavirus vaccine and method of treating bo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1373808